October 20, 2014 – Heart disease and stroke are the leading causes of death and disability among people with Type 2 ...
Pharmaceuticals
This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.
October 15, 2014 — Novartis Pharmaceuticals Canada Inc. revealed, in the largest heart failure study to date, that its ...
October 14, 2014 — Researchers have discovered a previously unknown cardiac molecule that could provide a key to ...
September 23, 2014 — New analyses and extended follow-up from the BRIGHT study demonstrated that bivalirudin remained ...
September 22, 2014 — According to a new study, patients receiving six months of dual antiplatelet therapy (DAPT) after ...
September 19, 2014 — The largest prospective longitudinal study of acute myocardial infarction (MI) patients offers ...
September 19, 2014 — A new study investigating different durations of triple therapy for anticoagulation after drug ...
September 12, 2014 — The first researcher in the world to discover that aspirin prevents a first attack, Charles H ...
September 3, 2014 –In patients who experienced an acute coronary syndrome (ACS) event (such as heart attack or unstable ...
August 25, 2014 — New data revealing the reduction in cardiovascular (CV) deaths with Novartis' LCZ696 in patients with ...
August 20, 2014 — AstraZeneca received confirmation from the United States Department of Justice that it is closing its ...
August 5, 2014 — The launch of several drugs with “extraordinary blockbuster potential” will cause the acute coronary ...
August 1, 2014 — Researchers at Wayne State University have made a fundamental discovery and, in subsequent ...
October 20, 2014